In vitro sensitivity of Plasmodium falciparum to halofantrine compared with chloroquine, quinine and mefloquine in the region of Bobo-Dioulasso, Burkina Faso (West Africa)

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.

Download / Buy Article:

Abstract:

The in vitro sensitivity of P. falciparum drug-resistant isolates was evaluated in the region of Bobo-Dioulasso during the 1995 and 1996 rainy seasons. Two routinely used antimalarials (chloroquine and quinine) and two new antimalarials (mefloquine and halofantrine) were assessed using 24-hour in vitro cultures with tritiated hypoxanthine and a parasite density <\>> 4,000/mul of blood. The proportion of chloroquine-resistant isolates was 20% in 1995 and 19% in 1996, whilst in 1996, the proportion of isolates resistant to halofantrine was greater than in 1995 (9.6% versus 1%). No significant differences were seen in the mean IC50 values in relation to the susceptibility of chloroquine-resistant or chloroquine-sensitive isolates to mefloquine and halofantrine. In the case of quinine, the mean IC50 values were significantly higher in chloroquine-resistant isolates than in chloroquine-sensitive ones. A significant positive correlation was found between the following IC50 values: chloroquine versus quinine, quinine versus mefloquine and mefloquine versus halofantrine.

Keywords: Malaria; Plasmodium falciparum; West Africa; chemosensitivity; halofantrine

Document Type: Research Article

Affiliations: 1: Centre Muraz/OCCGE, Malaria Chemoresistance Reference Centre, Parasitology and Entomology Laboratory Bobo-Dioulasso, Burkina Faso 2: Institut de Recherche en Sciences de Ia Sante/CNRST, Ouagadougou, Burkina Faso 3: SmithKline Beecham, Paris, France 4: Department of Paediatrics National Hospital, Bobo-Dioulasso, Burkina Faso

Publication date: May 1, 1998

Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more